Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 28191 | 173 | 52.3 | 90% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | PHARMACEUT PROTE | Address | 3 | 27% | 6% | 11 |
| 2 | PRE LIGAND BINDING ASSEMBLY DOMAIN PLAD | Author keyword | 3 | 100% | 2% | 3 |
| 3 | TUMOR NECROSIS FACTOR RECEPTOR TNFR | Author keyword | 2 | 67% | 1% | 2 |
| 4 | TNFR2 | Author keyword | 1 | 14% | 6% | 10 |
| 5 | TNFR1 SELECTIVE ANTAGONIST | Author keyword | 1 | 100% | 1% | 2 |
| 6 | XENP1595 | Author keyword | 1 | 100% | 1% | 2 |
| 7 | CD120B | Author keyword | 1 | 33% | 1% | 2 |
| 8 | COLCHICUM LUTEUM | Author keyword | 1 | 33% | 1% | 2 |
| 9 | AKT PKB ACTIVATION | Author keyword | 1 | 50% | 1% | 1 |
| 10 | ANTAGONISTIC ANTIBODY | Author keyword | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | PRE LIGAND BINDING ASSEMBLY DOMAIN PLAD | 3 | 100% | 2% | 3 | Search PRE+LIGAND+BINDING+ASSEMBLY+DOMAIN+PLAD | Search PRE+LIGAND+BINDING+ASSEMBLY+DOMAIN+PLAD |
| 2 | TUMOR NECROSIS FACTOR RECEPTOR TNFR | 2 | 67% | 1% | 2 | Search TUMOR+NECROSIS+FACTOR+RECEPTOR+TNFR | Search TUMOR+NECROSIS+FACTOR+RECEPTOR+TNFR |
| 3 | TNFR2 | 1 | 14% | 6% | 10 | Search TNFR2 | Search TNFR2 |
| 4 | TNFR1 SELECTIVE ANTAGONIST | 1 | 100% | 1% | 2 | Search TNFR1+SELECTIVE+ANTAGONIST | Search TNFR1+SELECTIVE+ANTAGONIST |
| 5 | XENP1595 | 1 | 100% | 1% | 2 | Search XENP1595 | Search XENP1595 |
| 6 | CD120B | 1 | 33% | 1% | 2 | Search CD120B | Search CD120B |
| 7 | COLCHICUM LUTEUM | 1 | 33% | 1% | 2 | Search COLCHICUM+LUTEUM | Search COLCHICUM+LUTEUM |
| 8 | AKT PKB ACTIVATION | 1 | 50% | 1% | 1 | Search AKT+PKB+ACTIVATION | Search AKT+PKB+ACTIVATION |
| 9 | ANTAGONISTIC ANTIBODY | 1 | 50% | 1% | 1 | Search ANTAGONISTIC+ANTIBODY | Search ANTAGONISTIC+ANTIBODY |
| 10 | HUMANIZED IGG | 1 | 50% | 1% | 1 | Search HUMANIZED+IGG | Search HUMANIZED+IGG |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | TRANSMEMBRANE TNF | 6 | 31% | 9% | 16 |
| 2 | PRELIGAND ASSEMBLY DOMAIN | 4 | 75% | 2% | 3 |
| 3 | SECRETED TNF | 1 | 31% | 2% | 4 |
| 4 | ANTAGONISTIC MUTANT TNF | 1 | 100% | 1% | 2 |
| 5 | 55 KDA TNF RECEPTOR | 1 | 23% | 2% | 3 |
| 6 | 55 KD | 1 | 50% | 1% | 1 |
| 7 | CELL SURFACE IMMOBILIZATION | 1 | 50% | 1% | 1 |
| 8 | SOLUBLE TNF | 1 | 29% | 1% | 2 |
| 9 | FACTOR RECEPTOR P60 | 0 | 33% | 1% | 1 |
| 10 | IMPRINTED POLYMER NANOSPHERES | 0 | 33% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1 | 2011 | 33 | 107 | 21% |
| Development of New Biologics through Creation of a Functional Cytokine Mutant | 2015 | 0 | 13 | 62% |
| The TNF superfamily in 2009: new pathways, new indications, and new drugs | 2009 | 44 | 48 | 15% |
| Tumor necrosis factor receptor cross-talk | 2011 | 45 | 83 | 12% |
| TNF receptor 2 pathway: drug target for autoimmune diseases | 2010 | 106 | 136 | 6% |
| An improved understanding of TNFL/TNFR interactions using structure-based classifications | 2012 | 5 | 62 | 18% |
| Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity | 2011 | 23 | 97 | 12% |
| Targeting TNF receptors in rheumatoid arthritis | 2012 | 14 | 69 | 7% |
| Small-molecule inhibitors of the interaction between TNF and TNFR | 2013 | 6 | 69 | 14% |
| TNF-alpha signalling and inflammation: interactions between old acquaintances | 2013 | 20 | 101 | 7% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PHARMACEUT PROTE | 3 | 27% | 6.4% | 11 |
| 2 | BIOPHARM INNOVAT UNIT | 1 | 50% | 0.6% | 1 |
| 3 | CLIN PLATFORMS SCI | 1 | 50% | 0.6% | 1 |
| 4 | KEY OBS | 1 | 50% | 0.6% | 1 |
| 5 | ADV EDUC DRUG DISCOVERY DEV | 1 | 29% | 1.2% | 2 |
| 6 | BACILLUS CALMETTE GUERIN | 0 | 33% | 0.6% | 1 |
| 7 | BIOMIMET SUR ES | 0 | 33% | 0.6% | 1 |
| 8 | MULTIDISCIPLINARY BIOL INVEST SAN LUIS IMIBI | 0 | 33% | 0.6% | 1 |
| 9 | NAT SCI IL | 0 | 33% | 0.6% | 1 |
| 10 | FRAUNHOFER INTER IAL ENGN BIOTECHNOL | 0 | 15% | 1.2% | 2 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000203192 | MORRIS HEPATOMA 5123//TNF RECEPTORS//ENDOGENOUS TNF ALPHA |
| 2 | 0.0000160843 | TAK1//TRAF4//TRAF5 |
| 3 | 0.0000158073 | DRUG INDUCED LUPUS//DRUG INDUCED LUPUS ERYTHEMATOSUS//TNF ALPHA ANTAGONISTS |
| 4 | 0.0000116170 | DCR3//DECOY RECEPTOR 3//TL1A |
| 5 | 0.0000099472 | NECROPTOSIS//RIP3//NECROSTATIN 1 |
| 6 | 0.0000096958 | LYMPHOTOXIN//LT BETA R//BTLA |
| 7 | 0.0000088734 | FN14//TWEAK//STWEAK |
| 8 | 0.0000075375 | D GALACTOSAMINE//BICYCLOL//CON A INDUCED HEPATITIS |
| 9 | 0.0000070556 | ENDOSIALIN//CD248//TEM1 |
| 10 | 0.0000069805 | ANTI TNF ALPHA THERAPIES//GENHOTEL RECH EUROPEEN POLYARTHRITE RHUMATOID//PATHOL RHEUMATOL |